PhD Candidate Arghavan Jahandideh defends her doctoral thesis this upcoming Friday, January 10th, 2025

MSc Arghavan Jahandide will have her public defence for her PhD thesis titeled :

MOLECULAR IMAGING OF AUTOIMMUNE MYOCARDITIS USING NEW PET TRACERS IN EXPERIMENTAL MODELS

The defence will be held in English on 10 January 2025 at 12.00 (TYKS, T-hospital, Risto Lahesmaa auditorium, Hämeentie 11, Turku). 

Our group PI Prof. MD, Antti Saraste (Turku PET Centre and Turku University Hospital) will act as the custos and the opponent will be Prof. MD, Kirsi Timonen (Hospital Nova of Central Finland, Jyväskylä).

The electronic disseration book can be found through our university library link https://urn.fi/URN:ISBN:978-951-29-9995-8

A brief review of the doctoral dissertation :

Myocarditis, an inflammatory heart condition, is difficult to diagnose because its symptoms can mimic many other illnesses. A common tool to detect heart inflammation is positron emission tomography/computed tomography (PET/CT) imaging with a sugar-like tracer called 18F-FDG. However, this tracer can also be taken up by healthy heart muscle, making it difficult to distinguish between healthy and inflamed tissue. To address this problem, my study explored the use of three alternative PET tracers that might more accurately detect active inflammation in the heart.
I tested three PET tracers for their ability to target inflammation in heart tissue in an experimental model of myocarditis: 18F-FOL, which binds to a specific receptor on activated immune cells; [68Ga]Ga-NODAGA-RGD, which targets molecules involved in new blood vessel formation; and [68Ga]Ga-DOTA-Siglec-9, which identifies proteins associated with white blood cell movement. PET/CT imaging showed that all three tracers had high uptake in inflamed heart tissue, whereas there was only minimal background signal in healthy heart tissue. The results were further confirmed with tissue samples of patients with myocarditis associated with sarcoidosis, a chronic systemic autoimmune disease.
This research found that 18F-FOL, [68Ga]Ga-NODAGA-RGD, and [68Ga]Ga-DOTA-Siglec-9 are promising PET tracers to detect active heart inflammation, and encourage further development as a possible diagnostic tools in human myocarditis.

PhD candidate Jenni Virta will defend her thesis on August 9th 2024

PhD Candidate Jenni Virta will defend her thesis on August 9th 2024

MSc Jenni Virta will defend her dissertation titeled

"POSITRON EMISSION TOMOGRAPHY IMAGING OF DISEASE ACTIVITY IN ATHEROSCLEROSIS"

at at the University of Turku on 09 August 2024 at 12.00 pm - 16.00 pm (TYKS T Hospital, Risto Lahesmaa auditorium, Hämeentie 11, 20520 Turku).

Opponent : Professor Sohvi Hörkkö  (University of Oulu)

Custos : Professor Antti Saraste (University of Turku)

Examination format : On site, Finnish.

The field of the dissertation is clinical physiology and nuclear medicine and conducted at Turku PET Centre, University of Turku, Finland.

The electronic book of her dissertation can be accessed via university's repository https://www.utupub.fi/handle/10024/178833

Summary of the dissertation:

Atherosclerosis is a progressive inflammatory disease in which fat and inflammatory cells, such as eating cells, accumulate on the walls of blood vessels. Atherosclerotic artery diseases, such as coronary artery disease, are the leading cause of death worldwide. Type 2 diabetes is an important risk factor for atherosclerosis, affecting an estimated more than 370 million people worldwide and increasing alarmingly among younger people. The eating cells of the artery wall play an important role in regulating the disease activity of atherosclerosis and can either prevent or promote the progression of the disease.

Positron emission tomography, or PET, is an imaging method that can be used to describe biological functions in living objects. PET imaging can be used in disease research, diagnostics and treatment monitoring. For the imaging of atherosclerosis, new specific markers are needed that target inflammation, more precisely, activated eating cells, which would make it possible to assess the disease activity of atherosclerosis.

The dissertation investigated the suitability of three new PET tracers 68Ga-NODAGA-exendin-4, (2S, 4R)-4-[18F]fluoroglutamine (18F-FGln) and 18F-AlF-NOTA-folate (18F-FOL) for imaging atherosclerosis disease activity. In addition, the effects of linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used as an antidiabetic drug, on atherosclerosis activity were investigated using PET imaging with the most commonly used 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) marker. The studies were conducted using experimental models of atherosclerosis and type 2 diabetes.

The results showed that 68Ga-NODAGA-exendin-4, 18F-FGln and 18F-FOL enable PET imaging of atherosclerotic plaque-eating cells. Treatment with linagliptin did not have the desired effect on atherosclerosis activity or fatty liver, although it improved sugar tolerance and reduced liver inflammation. The study provides new information on the possibilities of PET imaging of atherosclerosis disease activity.